Third Annual World Congress on the insulin resistance syndrome: Atherothrombotic disease

Diabetes Care

Volumn 29, Issue 8, 2006, Pages 1973-1980

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FIBRINOGEN RECEPTOR ANTAGONIST; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEPARIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METFORMIN; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR; PROSTACYCLIN; ROSIGLITAZONE; SIMVASTATIN; TYPHOID VACCINE;

ADIPOCYTE; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFECT; DRUG ELUTING STENT; HUMAN; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; STROKE; THROMBOSIS; VASCULAR DISEASE;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COAGULANTS; HUMANS; INSULIN RESISTANCE; SYNDROME; THROMBOSIS;

EID: 33746592506     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-zb08     Document Type: Conference Paper

References (69)

1. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140-2144, 2002
2. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102:2180-2184, 2000
3. Dunn EJ, Ariens RA, Grant PJ: The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48:1198-1206, 2005
4. Neel JV, Weder AB, Julius S: Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. Perspect Biol Med 42:44-74, 1998
5. Stern MP: Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes 44:369-374, 1995
6. Dunlap JC: Molecular bases for circadian clocks. Cell 96:271-290, 1999
7. Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, Laposky A, Losee-Olson S, Easton A, Jensen DR, Eckel RH, Takahashi JS, Bass J: Obesity and metabolic syndrome in circadian Clock mutant mice. Science 308:1043-1045, 2005
8. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361:13-20, 2003
9. Bonnefoy E, Steg PG, Chabaud S, Dubien PY, Lapostolle F, Boudet F, Lacroute JM, Dissait F, Vanzetto G, Leizorowicz A, Touboul P: Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial. Eur Heart J 26:1712-1718, 2005
10. Bypass Angioplasty Revascularization Investigation (BARI): Seven-year outcome in the BARI by treatment and diabetic status. J Am Coll Cardiol 35:1122-1129, 2000
11. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriureticpeptide. Circulation 105:1760-1763, 2002
12. Marx N: Diabetes and acute coronary syndromes: a cardiologist's view. Diab Vasc Dis Res 2:101-102, 2005
13. Grant PJ: Diabetes and acute coronary syndromes: a diabetologist's view. Diab Vasc Dis Res 2:103-104, 2005
14. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria: Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354:617-621, 1999
15. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M, the Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28:888-894, 2005
16. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342, 2004
17. Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL: Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) prevention trial. Am Heart J 148:883-888, 2004
18. Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM: Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28:1680-1689, 2005
19. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583-590, 2005
20. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW: Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 343:915-922, 2000
21. Cipollone F, Rocca B, Patrono C: Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24:246-255, 2004
22. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A, the Identification of New Elements of Plaque Stability (INES) Study Group: A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291: 2221-2228, 2004
23. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A: Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104:921-927, 2001
24. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108:1070-1077, 2003
25. Marx N, Walcher D, Raichle C, Aleksic M, Bach H, Grub M, Hombach V, Libby P, Zieske A, Homma S, Strong J: C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol 24:540-545, 2004
26. Valtonen V, Kuikka A, Syrjanen J: Thrombo-embolic complications in bacteraemic infections. Eur Heart J 14 (Suppl. K):20-23, 1993
27. Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Maiwald M, Rohlfs M, Suhr H, Fiehn W, Becher H, et al.: Recent infection as a risk factor for cerebrovascular ischemia. Stroke 26:373-379, 1995
28. Mamode N, Cobbe S, Pollock JG: Infarcts after surgery. BMJ 310:1215-1216, 1995
29. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H: Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 351:1467-1471, 1998
30. Vallance P, Collier J, Bhagat K: Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 349:1391-1392, 1997
31. Clapp BR, Hirschfield GM, Storry C, Gallimore JR, Stidwill RP, Singer M, Deanfield JE, MacAllister RJ, Pepys MB, Vallance P, Hingorani AD: Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 111:1530-1536, 2005
32. Skarfors ET, Lithell HO, Selinus I: Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens 9:217-223, 1991
33. Taittonen L, Uhari M, Nuutinen M, Turtinen J, Pokka T, Akerblom HK: Insulin and blood pressure among healthy children: cardiovascular risk in young Finns. Am J Hypertens 9:194-199, 1996
34. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 161:361-366, 2001
35. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Munzel T: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97:e53-e59, 2005
36. Lowe GD, Middleton SM, Hay ID, Beastall GH, Singaraveloo M, Cohen HN, Thomson JA, Forbes CD, Prentice CR: Effects of growth hormone, glucose and insulin on the factor VIII complex. Thromb Res 28:201-211, 1982
37. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101:975-980, 2000
38. Collins R, Armitage J, Parish S, Sleigh P, Peto R, the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
39. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
40. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM: Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 322:1389-1393, 2001
41. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
42. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141:413-420, 2004
43. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, Prins MH, Girolami A: An association between atherosclerosis and venous thrombosis. N Engl J Med 348:1435-1441, 2003
44. Becattini C, Agnelli G, Prandoni P, Silingardi M, Salvi R, Taliani MR, Poggio R, Imberti D, Ageno W, Pogliani E, Porro F, Casazza F: A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 26:77-83, 2005
45. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR: Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 162:1182-1189, 2002
46. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695, 2005
47. Lowe GD: Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 3:1618-1627, 2005
48. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH: Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in type 2 diabetic men with and without coronary heart disease. Diabetologia 47:1557-1565, 2004
49. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH: The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 181:101-108, 2005
50. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152:897-907, 2000
51. Mansfield MW, Heywood DM, Grant PJ: Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 94:2171-2176, 1996
52. Juhan-Vague I, Alessi MC, Mavri A, Morange PE: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575-1579, 2003
53. LaMonte MJ, Durstine JL, Yanowitz FG, Lim T, DuBose KD, Davis P, Ainsworth BE: Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation 106:403-406, 2002
54. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477-1482, 1998
55. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387-1397, 2004
56. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A the Fibrinogen Studies Collaboration: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799-1809, 2005
57. D'Aiuto F, Casas JP, Shah T, Humphries SE, Hingorani AD, Tonetti MS: C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 179:413-417, 2005
58. de Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ: The genetics of haemostasis: a twin study. Lancet 357:101-105, 2001
59. Freeman MS, Mansfield MW, Barrett JH, Grant PJ: Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. Arterioscler Thromb Vasc Biol 22:506-510, 2002
60. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H: Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 27:907-911, 2003
61. Wellen KE, Hotamisligil GS: Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785-1788, 2003
62. Antithrombotic Trialists' Collaboration: Collaborative metaanalysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002
63. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, Masuda Y: Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 87:596-602, 2000
64. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 153:17-23, 1998
65. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45:1925-1931, 2005
66. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W: Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23:283-288, 2003
67. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W, Marx N: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25:1804-1809, 2005
68. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27:2654-2660, 2004
69. Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M: Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112:2792-2798, 2005